Temozolomide 250 mg | TMOZOLMIDE 250

Description

TMOZOLMIDE 250 is a prescription anticancer medication formulated with Temozolomide 250 mg, widely used in the treatment of brain tumors and other specific cancers. Temozolomide belongs to the class of alkylating agents, which work by interfering with the DNA of cancer cells, preventing their replication and growth. This targeted mechanism helps slow down tumor progression and improves patient outcomes. Temozolomide is particularly effective in treating glioblastoma multiforme, anaplastic astrocytoma, and other aggressive brain cancers. It is often prescribed alongside radiotherapy or as maintenance therapy following surgical intervention to enhance therapeutic efficacy. Uses TMOZOLMIDE 250 is primarily indicated for: Glioblastoma Multiforme (GBM): Used in combination with radiotherapy to treat newly diagnosed cases or as maintenance therapy. Anaplastic Astrocytoma: Helps slow tumor progression in adult patients who have previously received chemotherapy or radiotherapy. Other Malignant Brain Tumors: Off-label use may be considered under medical supervision. Combination Therapy: Often used alongside other anticancer treatments for enhanced efficacy. Temozolomide is effective because it can cross the blood-brain barrier, directly targeting tumor cells in the central nervous system. Benefits 1. Effective Tumor Control Temozolomide slows cancer cell replication, reducing tumor growth and improving disease management. 2. Oral Convenience Available in oral capsule form, TMOZOLMIDE 250 provides a non-invasive treatment option, which is easier for patients compared to intravenous chemotherapy. 3. Combination Therapy Support Works synergistically with radiotherapy and other chemotherapeutic agents, enhancing overall treatment outcomes. 4. Brain Penetration Unlike many chemotherapeutic agents, Temozolomide can cross the blood-brain barrier, making it effective against central nervous system tumors. 5. Maintenance Therapy Used post-radiotherapy or surgery to help prolong remission and prevent tumor recurrence. Dosage Recommended Dose: Dosage of TMOZOLMIDE 250 is individualized based on body surface area (mg/m²), type of tumor, treatment phase, and patient tolerance. Administration: Typically taken once daily for 5 consecutive days in a 28-day cycle, but exact scheduling should follow the oncologist’s prescription. With or Without Food: Capsules can be taken with or without meals, but should be swallowed whole with water. Important: Never alter the dose or stop treatment without consulting the oncologist, as this may reduce effectiveness or increase risk of tumor progression. Side Effects TMOZOLMIDE 250 is generally well tolerated under medical supervision. Common side effects may include: Nausea and vomiting Fatigue or weakness Loss of appetite Constipation or diarrhea Headache Serious Side Effects (Require Immediate Attention) Low blood cell counts leading to anemia, infections, or bleeding tendencies Severe allergic reactions Liver or kidney function abnormalities Patients undergoing treatment are usually monitored regularly through blood tests and liver function tests to ensure safety. Precautions and Warnings Pregnancy and Breastfeeding: Not recommended due to potential harm to the fetus or infant. Immune Suppression: May reduce immunity; avoid contact with infected individuals. Pre-existing Conditions: Caution in patients with liver, kidney, or bone marrow disorders. Drug Interactions: Inform your doctor about other medications, supplements, or herbal products. Alcohol and Smoking: Avoid alcohol and smoking, as they may reduce treatment efficacy. Storage: Keep capsules in a cool, dry place, away from direct sunlight and children’s reach. Conclusion TMOZOLMIDE 250, containing Temozolomide 250 mg, is a trusted oral anticancer therapy for patients with malignant brain tumors such as glioblastoma multiforme and anaplastic astrocytoma. Its ability to penetrate the blood-brain barrier, combined with effective DNA-targeting action, makes it a cornerstone in modern oncology treatment. When used under careful medical supervision, TMOZOLMIDE 250 not only slows tumor progression but also supports combination therapy and maintenance regimens, improving patient outcomes and quality of life. With regular monitoring and adherence to prescribed dosage, TMOZOLMIDE 250 provides a safe, effective, and convenient solution for managing aggressive brain cancers.